Life Technologies reported after the close of today's market that its fourth-quarter revenues rose 7 percent to $932.3 million (exceeding Wall Street estimates of $929.4 million) year over year with 11% sales increases for its Genetic Systems and Cell Systems divisions.
The company posted a net profit of $70.7 million, or 37 cents per share, compared with a profit of $48.9 million, or 26 cents per share, a year ago.
It projected 2011 revenue growth in the mid-single digits and forecast earnings excluding items of $3.80 to $3.95 per share. Analysts' on average are looking for 2011 earnings of $3.86 per share for the company.
-Jesus
Thursday, February 3, 2011
Illinois Tool Works earnings report
Illinois Tool Works reported their Q4 earnings and the earnings per share were $0.79 versus the $0.80 predicted by the analysts. The company's fourth-quarter profits fell by 23% as prior year. The decrease was primarily due to a big tax cut recorded in 2009. The last year tax benefit gave an extra 37 cents boost to EPS. For the whole year the company earned a total of $3.03 per share or a total of $1.53 billion compared to $1.49 per share and $947 million in 2009.
Even though the profits decreased the revenue for the fourth quarter was up by 11%. The best preforming segments were the Power Systems and Electronics which contribute almost 23% growth in revenue, and Welding Equipment increased their revenue by 18%. The total revenue for the year was $15.87 billion from $13.88 billion in 2009.
The volume of trades for the day was double the daily average, and despite not beating the analyst estimates the stock the stock closed the day with only a loss of 1.3% or $0.70.
The company is very optimistic on their first quarter earnings prediction which are higher then the estimates on the street. The company predicted 12% to 15% earnings growth for the first quarter, which will result in 81 cents to 87 cents EPS. Analysts predict earnings to be 76 cents per share a 10.6% growth.
Roman Beleuta
Even though the profits decreased the revenue for the fourth quarter was up by 11%. The best preforming segments were the Power Systems and Electronics which contribute almost 23% growth in revenue, and Welding Equipment increased their revenue by 18%. The total revenue for the year was $15.87 billion from $13.88 billion in 2009.
The volume of trades for the day was double the daily average, and despite not beating the analyst estimates the stock the stock closed the day with only a loss of 1.3% or $0.70.
The company is very optimistic on their first quarter earnings prediction which are higher then the estimates on the street. The company predicted 12% to 15% earnings growth for the first quarter, which will result in 81 cents to 87 cents EPS. Analysts predict earnings to be 76 cents per share a 10.6% growth.
Roman Beleuta
Tuesday, February 1, 2011
Novartis 4Q10 1/27/2011
Novartis released earnings Thursday, and reported $14.2 billion in sales for the fourth quarter and $50.6 billion in sales for year 2010. Novartis increased their fourth quarter sales by $1.3 billion, or 10%, from fourth quarter 2009, and increased their annual sales by $6.3 billion, representing an increase of 14%. In addition to sales, profit also exceeded last year’s numbers, but did not exceed analyst expectations. Profits for the year jumped to $10 billion, representing an increase of 18% over the previous year’s $8.4 billion in profits. Quarterly profits fell by 2% from $2.32 billion to $2.27 billion.
Despite fairly positive numbers, Novartis shares dropped 2.7%, as the reported earnings did not meet analyst recommendations. Wall Street analysts had expected Novartis to report earnings of $1.25 per share, but the company only returned $1.14. The earnings underperformed analyst expectations mainly due to restructuring charges and currency impacts. However, the company praised its acquisition of Alcon, and expects the new eye-care division to be a driver of earnings growth in the future. In addition, the company saw 13 major products approved, and filed 16 new products during the 2010 year. Novartis saw strong growth in its generic division, which saw sales increase 14% from $7.5 billion to $8.5 billion. The generic arm of Novartis capitalized on patent expirations of other large pharmaceutical companies such as Sanofi-Aventis and Merck. Novartis created generic version of Sanofi-Aventis’ Lovenox, a blood thinning drug, and Cozaar, a major cardiovascular drug created by Merck. Novartis also has some potential blockbuster drugs in the pipeline. The company is currently working on an experimental respiratory drug called QVA149, which is expected to be a major drug if it is approved. A new blockbuster drug is necessary, as Novartis is about to face patent expirations of some of its biggest drugs. Diovan, the company’s best-selling heart drug, drove $6 billion in sales in 2009, and is now facing patent expiration in 2011. In addition, Gilvec drove nearly $4 billion in sales, and is facing patent expiration in 2015.
To summarize, Novartis saw increase in annual and quarterly sales, and an increase in annual earnings. Despite these increases, the company missed analyst expectations, and the stock dropped by 2.7%. Going forward, the company needs to find a new blockbuster drug to help alleviate the earnings loss that will come when two major drugs, Diovan and Gilvec, face patent expiration. Considering the patent expirations the company is facing, and the uncertainty surrounding healthcare reform, I am cautious about Novartis’ return potential and its place in our portfolio.
-Ryan M. Kennedy
Despite fairly positive numbers, Novartis shares dropped 2.7%, as the reported earnings did not meet analyst recommendations. Wall Street analysts had expected Novartis to report earnings of $1.25 per share, but the company only returned $1.14. The earnings underperformed analyst expectations mainly due to restructuring charges and currency impacts. However, the company praised its acquisition of Alcon, and expects the new eye-care division to be a driver of earnings growth in the future. In addition, the company saw 13 major products approved, and filed 16 new products during the 2010 year. Novartis saw strong growth in its generic division, which saw sales increase 14% from $7.5 billion to $8.5 billion. The generic arm of Novartis capitalized on patent expirations of other large pharmaceutical companies such as Sanofi-Aventis and Merck. Novartis created generic version of Sanofi-Aventis’ Lovenox, a blood thinning drug, and Cozaar, a major cardiovascular drug created by Merck. Novartis also has some potential blockbuster drugs in the pipeline. The company is currently working on an experimental respiratory drug called QVA149, which is expected to be a major drug if it is approved. A new blockbuster drug is necessary, as Novartis is about to face patent expirations of some of its biggest drugs. Diovan, the company’s best-selling heart drug, drove $6 billion in sales in 2009, and is now facing patent expiration in 2011. In addition, Gilvec drove nearly $4 billion in sales, and is facing patent expiration in 2015.
To summarize, Novartis saw increase in annual and quarterly sales, and an increase in annual earnings. Despite these increases, the company missed analyst expectations, and the stock dropped by 2.7%. Going forward, the company needs to find a new blockbuster drug to help alleviate the earnings loss that will come when two major drugs, Diovan and Gilvec, face patent expiration. Considering the patent expirations the company is facing, and the uncertainty surrounding healthcare reform, I am cautious about Novartis’ return potential and its place in our portfolio.
-Ryan M. Kennedy
Sunday, January 30, 2011
Novartis 4Q10 1/27/2011
Novartis released earnings Thursday, and reported $14.2 billion in sales for the fourth quarter and $50.6 billion in sales for year 2010. Novartis increased their fourth quarter sales by $1.3 billion, or 10%, from fourth quarter 2009, and increased their annual sales by $6.3 billion, representing an increase of 14%. In addition to sales, profit also exceeded last year’s numbers, but did not exceed analyst expectations. Profits for the year jumped to $10 billion, representing an increase of 18% over the previous year’s $8.4 billion in profits. Quarterly profits fell by 2% from $2.32 billion to $2.27 billion.
Despite fairly positive numbers, Novartis shares dropped 2.7%, as the reported earnings did not meet analyst recommendations. Wall Street analysts had expected Novartis to report earnings of $1.25 per share, but the company only returned $1.14. The earnings underperformed analyst expectations mainly due to restructuring charges and currency impacts. However, the company praised its acquisition of Alcon, and expects the new eye-care division to be a driver of earnings growth in the future. In addition, the company saw 13 major products approved, and filed 16 new products during the 2010 year. Novartis saw strong growth in its generic division, which saw sales increase 14% from $7.5 billion to $8.5 billion. The generic arm of Novartis capitalized on patent expirations of other large pharmaceutical companies such as Sanofi-Aventis and Merck. Novartis created generic version of Sanofi-Aventis’ Lovenox, a blood thinning drug, and Cozaar, a major cardiovascular drug created by Merck. Novartis also has some potential blockbuster drugs in the pipeline. The company is currently working on an experimental respiratory drug called QVA149, which is expected to be a major drug if it is approved. A new blockbuster drug is necessary, as Novartis is about to face patent expirations of some of its biggest drugs. Diovan, the company’s best-selling heart drug, drove $6 billion in sales in 2009, and is now facing patent expiration in 2011. In addition, Gilvec drove nearly $4 billion in sales, and is facing patent expiration in 2015.
In conclusion, Novartis saw increase in annual and quarterly sales, and an increase in annual earnings. Despite these increases, the company missed analyst expectations, and the stock dropped by 2.7%. Going forward, the company needs to find a new blockbuster drug to help alleviate the earnings loss that will come when two major drugs, Diovan and Gilvec, face patent expiration. Considering the patent expirations the company is facing, and the uncertainty surrounding healthcare reform, I am cautious about Novartis’ return potential and its place in our portfolio.
-Ryan M. Kennedy
Friday, January 28, 2011
Ford 4Q10 Earnings 1/27/11
Ford Motor reported its best full-year profit in more than a decade, but weaker-than-expected fourth-quarter earnings. Net profit for 2010 totaled $6.6 billion, or $1.66 per share, an increase of $3.8 billion above 2009. However, Ford’s fourth -quarter earnings fell 79% to $190 million. These results include a previously disclosed one time charge of $960 million as part of its balance sheet restructuring. Ford fell short of analyst earnings estimates of $0.48 by 37%, reporting earnings of only $0.30. Ford had beaten expectations for each of the past seven quarters.
4Q earnings also showed Ford Europe’s operating loss of $51 million, compared with a $253 million profit a year earlier. Chief financial officer, Lewis Booth described the surprising results in Europe as “a little bit of a disappointment”. He also said: “We were very clear, though, that we were not going to chase market share.” The European operation is expected to return to profitability this year.
In 2010, Ford paid over $14.5 billion in debt, ending the year with $19.1 billion in debt. Cash revenues totaled $20.5 billion shifting Ford from $8.7 billion in net debt a year ago to net cash of $1.4 billion. Ford plans to continue to reduce the amount of debt they have on their balance sheet through 2011.
Ford shares were hit by the weak earnings, falling by $2.39 or 12.72% to 16.40. Other then the stock plunge the earnings report for Ford was great. Ford showed its ability to grow profits in 2010 and is expecting to continue in 2011. A key concern looking to the future will be whether or not Ford can maintain healthy profit margins.
- Michael Biagi, Junior Analyst
4Q earnings also showed Ford Europe’s operating loss of $51 million, compared with a $253 million profit a year earlier. Chief financial officer, Lewis Booth described the surprising results in Europe as “a little bit of a disappointment”. He also said: “We were very clear, though, that we were not going to chase market share.” The European operation is expected to return to profitability this year.
In 2010, Ford paid over $14.5 billion in debt, ending the year with $19.1 billion in debt. Cash revenues totaled $20.5 billion shifting Ford from $8.7 billion in net debt a year ago to net cash of $1.4 billion. Ford plans to continue to reduce the amount of debt they have on their balance sheet through 2011.
Ford shares were hit by the weak earnings, falling by $2.39 or 12.72% to 16.40. Other then the stock plunge the earnings report for Ford was great. Ford showed its ability to grow profits in 2010 and is expecting to continue in 2011. A key concern looking to the future will be whether or not Ford can maintain healthy profit margins.
- Michael Biagi, Junior Analyst
Ford 4Q10 Earnings 1/27/11
Ford Motor reported its best full-year profit in more than a decade, but weaker-than-expected fourth-quarter earnings. Net profit for 2010 totaled $6.6 billion, or $1.66 per share, an increase of $3.8 billion above 2009. However, Ford’s fourth -quarter earnings fell 79% to $190 million. These results include a previously disclosed one time charge of $960 million as part of its balance sheet restructuring. Ford fell short of analyst earnings estimates of $0.48 by 37%, reporting earnings of only $0.30. Ford had beaten expectations for each of the past seven quarters.
4Q earnings also showed Ford Europe’s operating loss of $51 million, compared with a $253 million profit a year earlier. Chief financial officer, Lewis Booth described the surprising results in Europe as “a little bit of a disappointment”. He also said: “We were very clear, though, that we were not going to chase market share.” The European operation is expected to return to profitability this year.
In 2010, Ford paid over $14.5 billion in debt, ending the year with $19.1 billion in debt. Cash revenues totaled $20.5 billion shifting Ford from $8.7 billion in net debt a year ago to net cash of $1.4 billion. Ford plans to continue to reduce the amount of debt they have on their balance sheet through 2011.
Ford shares were hit by the weak earnings falling by $2.39 or 12.72% to 16.40. Other then the stock plunge the earnings report for Ford was great. Ford showed its ability to grow profits in 2010 and is expecting to continue in 2011. A key concern looking to the future will be whether or not Ford can maintain healthy profit margins.
- Michael Biagi, Junior Analyst
Verizon Communications (VZ)- Earnings Release
Verizon Communications released fourth quarter earnings of $0.54 per share missing analyst expectations of $0.55 per share.
Verizon Wireless has experienced a 7.7% increase in service revenue and a 25.5% increase in its data revenue from 4th Quarter 2009.
Verizon’s Wireline segment added 197,000 Fios internet users and 182,000 Fios TV subscribers in the 4th Quarter of FY 2010.
On January 11th 2010 Verizon Wireless announced that it would begin carrying the iPhone 4 which will be available to Verizon Wireless subscribers in February of 2011. Verizon’s ability to begin distributing the iPhone 4 as one of its premier mobile devices is expected to provide substantial wireless service and data growth. Despite the iPhone’s ability to increase customer and data growth, many analysts are concerned of Verizon’s ability to support the influx of data usage. Verizon Wireless has been a market leader in service quality over the last years. Deterioration of Verizon’s wireless network could potentially cause material problems for the company’s growth and ability to maintain favorable churn. Management has stated that it is fully confident in its network, however this is an issue that UASBIG analysts will continue to monitor closely.
~Chad
Verizon Wireless has experienced a 7.7% increase in service revenue and a 25.5% increase in its data revenue from 4th Quarter 2009.
Verizon’s Wireline segment added 197,000 Fios internet users and 182,000 Fios TV subscribers in the 4th Quarter of FY 2010.
On January 11th 2010 Verizon Wireless announced that it would begin carrying the iPhone 4 which will be available to Verizon Wireless subscribers in February of 2011. Verizon’s ability to begin distributing the iPhone 4 as one of its premier mobile devices is expected to provide substantial wireless service and data growth. Despite the iPhone’s ability to increase customer and data growth, many analysts are concerned of Verizon’s ability to support the influx of data usage. Verizon Wireless has been a market leader in service quality over the last years. Deterioration of Verizon’s wireless network could potentially cause material problems for the company’s growth and ability to maintain favorable churn. Management has stated that it is fully confident in its network, however this is an issue that UASBIG analysts will continue to monitor closely.
~Chad
Subscribe to:
Posts (Atom)